


The objective of the Fund is to provide capital growth.
| Name | % Net Assets | 
|---|---|
| Royal Dutch Shell 'B' | 5.2% | 
| BP | 4.9% | 
| British American Tobacco | 4.6% | 
| HSBC | 4.5% | 
| Vodafone | 3.8% | 
| GlaxoSmithKline | 3.7% | 
| AstraZeneca | 3.6% | 
| Centrica | 3.2% | 
| Aviva | 3.0% | 
| Standard Chartered | 2.9% | 
| Key | % Net Assets | 
|---|---|
| 5.2% | |
| 4.9% | |
| 4.6% | |
| 4.5% | |
| 80.8% | 
| Date | 23-Jun-2023 | 
|---|---|
| NAV | 166.96p | 
| Currency | GBP | 
| Change | -0.83p | 
| % | -0.49% | 
| YTD change | 166.96p | 
| YTD % | n/a | 
| Fund Inception | 16/12/2005 | 
|---|---|
| Fund Manager | Pan European Equities Team | 
| TER | - | 
| Minimum Investment | |
|---|---|
| Initial | £500 | 
| Additional | £100 | 
| Savings | £50 | 
| Charges | |
|---|---|
| Initial | 4.25% | 
| Annual Mang't | 1.50% | 
| Exit | n/a | 
| Name | % | 
|---|---|
| Standard deviation | 0.01 | 
| Sharpe ratio | 0.12 | 
You are here: research